14A-1110805
USP
This invention discovered that a phytogalactolipid-enriched fraction (CRA) obtained from Crassocephalum rabens (Benth.) S. Moore efficiently inhibited tumor growth in drug-sensitive and resistant colorectal cancer (CRC) mice. CRA treatment attracted an abundance of B cells into the tumor, consequently enhancing the anti-tumor antibodies in sera and inducing class-switch from IgM to IgG1, IgG2, and IgG3. CRA-antisera specifically recognized surface antigen on the membrane of cancer cells. CRA-antisera not only revealed cytotoxicity against cancer cells but also induced antibody-dependent cell cytotoxicity, phagocytosis, and complement-dependent cytotoxicity. CRA activated STAT3 and cMaf and let T cells secrete IL-21 which induced B cells differentiation through IL-21R/STAT3/Blimp-1 pathway. The significance of these studies indicated CRA could regulate the T cells to offer the B cell activation and trigger anti-tumor antibodies to impede drug-resistant CRC progression.
- Phytogalactolipids effectively inhibit tumor growth in drug-resistant colorectal cancer by triggering humoral immunity.
- Phytogalactolipids effectively increase the production of anti-tumor antibodies and induces class-switching by activating B cell differentiation.
- Phytogalactolipids effectively inhibit tumor growth of drug-resistant colorectal cancer by inducing antibody-dependent cytotoxicity.
- Phytogalactolipids are novel humoral immuotherapeutics for cancer diseases.
- Humoral immunotherapeutics for colorectal cancer or drug-resistant colorectal cancer
- Humoral immune modulator
- Cancer vaccine
Yu-Ling Lin, Li-Fen Shyur
If you are interested in this technology, please fill in the information on the webpage under the manufacturer option (Request for Technology Licensing, Material Transfer, or Sponsored Research) on the website of this office

A humoral immune-modulatory phytogalactolipids extract for drug-resistant colorectal cancer